Recent submissions

  • Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. 

    Johnston, S; O'Shaughnessy, J; Martin, M; Huober, J; Toi, M; Sohn, J; André, VAM; Martin, HR; Hardebeck, MC; Goetz, MP (2021-06-22)
    In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2- advanced breast cancer. We report data for clinically prognostic ...
  • Investigating a range of late effects of Hodgkin lymphoma treatments 

    Macklin-Doherty, A (2021-01-31)
    Dramatic improvement in Hodgkin lymphoma (HL) survival rates over recent decades has come at significant cost: treatment-related late effects which are epitomised in female HL patients treated at young ages. The aims of ...
  • Ubiquitylation of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen clearance. 

    Garcia, LR; Tenev, T; Newman, R; Haich, RO; Liccardi, G; John, SW; Annibaldi, A; Yu, L; Pardo, M; Young, SN; Fitzgibbon, C; Fernando, W; Guppy, N; Kim, H; Liang, L-Y; Lucet, IS; Kueh, A; Roxanis, I; Gazinska, P; Sims, M; Smyth, T; Ward, G; Bertin, J; Beal, AM; Geddes, B; Choudhary, JS; Murphy, JM; Aurelia Ball, K; Upton, JW; Meier, P (2021-06-07)
    Necroptosis is a lytic, inflammatory form of cell death that not only contributes to pathogen clearance but can also lead to disease pathogenesis. Necroptosis is triggered by RIPK3-mediated phosphorylation of MLKL, which ...
  • Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. 

    Zatreanu, D; Robinson, HMR; Alkhatib, O; Boursier, M; Finch, H; Geo, L; Grande, D; Grinkevich, V; Heald, RA; Langdon, S; Majithiya, J; McWhirter, C; Martin, NMB; Moore, S; Neves, J; Rajendra, E; Ranzani, M; Schaedler, T; Stockley, M; Wiggins, K; Brough, R; Sridhar, S; Gulati, A; Shao, N; Badder, LM; Novo, D; Knight, EG; Marlow, R; Haider, S; Callen, E; Hewitt, G; Schimmel, J; Prevo, R; Alli, C; Ferdinand, A; Bell, C; Blencowe, P; Bot, C; Calder, M; Charles, M; Curry, J; Ekwuru, T; Ewings, K; Krajewski, W; MacDonald, E; McCarron, H; Pang, L; Pedder, C; Rigoreau, L; Swarbrick, M; Wheatley, E; Willis, S; Wong, AC; Nussenzweig, A; Tijsterman, M; Tutt, A; Boulton, SJ; Higgins, GS; Pettitt, SJ; Smith, GCM; Lord, CJ (2021-06-17)
    To identify approaches to target DNA repair vulnerabilities in cancer, we discovered nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the polymerase function of DNA polymerase Polθ, including ...
  • Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation. 

    Shamseddin, M; De Martino, F; Constantin, C; Scabia, V; Lancelot, A-S; Laszlo, C; Ayyannan, A; Battista, L; Raffoul, W; Gailloud-Matthieu, M-C; Bucher, P; Fiche, M; Ambrosini, G; Sflomos, G; Brisken, C
    Hormonal contraception exposes women to synthetic progesterone receptor (PR) agonists, progestins, and transiently increases breast cancer risk. How progesterone and progestins affect the breast epithelium is poorly ...
  • Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. 

    Rugo, HS; Cristofanilli, M; Loibl, S; Harbeck, N; DeMichele, A; Iwata, H; Park, YH; Brufsky, A; Theall, KP; Huang, X; McRoy, L; Bananis, E; Turner, NC
    <h4>Background</h4>This analysis investigated whether baseline characteristics affect the survival benefit derived from palbociclib-fulvestrant and the optimal timing of cyclin-dependent kinase 4/6 inhibitor therapy for ...
  • Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis. 

    Jungwirth, U; van Weverwijk, A; Evans, RJ; Jenkins, L; Vicente, D; Alexander, J; Gao, Q; Haider, S; Iravani, M; Isacke, CM (2021-06-10)
    Profiling studies have revealed considerable phenotypic heterogeneity in cancer-associated fibroblasts (CAFs) present within the tumour microenvironment, however, functional characterisation of different CAF subsets is ...
  • Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). 

    Biganzoli, L; Battisti, NML; Wildiers, H; McCartney, A; Colloca, G; Kunkler, IH; Cardoso, M-J; Cheung, K-L; de Glas, NA; Trimboli, RM; Korc-Grodzicki, B; Soto-Perez-de-Celis, E; Ponti, A; Tsang, J; Marotti, L; Benn, K; Aapro, MS; Brain, EGC
    Breast cancer is increasingly prevalent in older adults and is a substantial part of routine oncology practice. However, management of breast cancer in this population is challenging because the disease is highly heterogeneous ...
  • Deep Learning Enables Individual Xenograft Cell Classification in Histological Images by Analysis of Contextual Features. 

    Juppet, Q; De Martino, F; Marcandalli, E; Weigert, M; Burri, O; Unser, M; Brisken, C; Sage, D
    Patient-Derived Xenografts (PDXs) are the preclinical models which best recapitulate inter- and intra-patient complexity of human breast malignancies, and are also emerging as useful tools to study the normal breast ...
  • Sox11 regulates mammary tumour-initiating and metastatic capacity in Brca1-deficient mouse mammary tumour cells. 

    Tsang, SM; Kim, H; Oliemuller, E; Newman, R; Boateng, N-A; Guppy, N; Howard, BA (2021-05-10)
    Little is known about the role of Sox11 in the regulation of mammary progenitor cells. Sox11 is expressed by mammary bud epithelial cells during embryonic mammary gland development and is not detected in mammary epithelial ...
  • A simple digital image analysis system for automated Ki67 assessment in primary breast cancer. 

    Alataki, A; Zabaglo, L; Tovey, H; Dodson, A; Dowsett, M
    <h4>Aims</h4>Ki67 is a well-established immunohistochemical marker associated with cell proliferation that has prognostic and predictive value in breast cancer. Quantitative evaluation of Ki67 is traditionally performed ...
  • Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. 

    Baxter, JS; Johnson, N; Tomczyk, K; Gillespie, A; Maguire, S; Brough, R; Fachal, L; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Ahearn, TU; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arndt, V; Aronson, KJ; Augustinsson, A; Becher, H; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Bogdanova, NV; Bojesen, SE; Brenner, H; Brucker, SY; Cai, Q; Campa, D; Canzian, F; Castelao, JE; Chan, TL; Chang-Claude, J; Chanock, SJ; Chenevix-Trench, G; Choi, J-Y; Clarke, CL; NBCS Collaborators; Colonna, S; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Daly, MB; Devilee, P; Dörk, T; Dossus, L; Dwek, M; Eccles, DM; Ekici, AB; Eliassen, AH; Engel, C; Fasching, PA; Figueroa, J; Flyger, H; Gago-Dominguez, M; Gao, C; García-Closas, M; García-Sáenz, JA; Ghoussaini, M; Giles, GG; Goldberg, MS; González-Neira, A; Guénel, P; Gündert, M; Haeberle, L; Hahnen, E; Haiman, CA; Hall, P; Hamann, U; Hartman, M; Hatse, S; Hauke, J; Hollestelle, A; Hoppe, R; Hopper, JL; Hou, M-F; kConFab Investigators; ABCTB Investigators; Ito, H; Iwasaki, M; Jager, A; Jakubowska, A; Janni, W; John, EM; Joseph, V; Jung, A; Kaaks, R; Kang, D; Keeman, R; Khusnutdinova, E; Kim, S-W; Kosma, V-M; Kraft, P; Kristensen, VN; Kubelka-Sabit, K; Kurian, AW; Kwong, A; Lacey, JV; Lambrechts, D; Larson, NL; Larsson, SC; Le Marchand, L; Lejbkowicz, F; Li, J; Long, J; Lophatananon, A; Lubiński, J; Mannermaa, A; Manoochehri, M; Manoukian, S; Margolin, S; Matsuo, K; Mavroudis, D; Mayes, R; Menon, U; Milne, RL; Mohd Taib, NA; Muir, K; Muranen, TA; Murphy, RA; Nevanlinna, H; O'Brien, KM; Offit, K; Olson, JE; Olsson, H; Park, SK; Park-Simon, T-W; Patel, AV; Peterlongo, P; Peto, J; Plaseska-Karanfilska, D; Presneau, N; Pylkäs, K; Rack, B; Rennert, G; Romero, A; Ruebner, M; Rüdiger, T; Saloustros, E; Sandler, DP; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Shah, M; Shen, C-Y; Shu, X-O; Simard, J; Southey, MC; Stone, J; Surowy, H; Swerdlow, AJ; Tamimi, RM; Tapper, WJ; Taylor, JA; Teo, SH; Teras, LR; Terry, MB; Toland, AE; Tomlinson, I; Truong, T; Tseng, C-C; Untch, M; Vachon, CM; van den Ouweland, AMW; Wang, SS; Weinberg, CR; Wendt, C; Winham, SJ; Winqvist, R; Wolk, A; Wu, AH; Yamaji, T; Zheng, W; Ziogas, A; Pharoah, PDP; Dunning, AM; Easton, DF; Pettitt, SJ; Lord, CJ; Haider, S; Orr, N; Fletcher, O
    A combination of genetic and functional approaches has identified three independent breast cancer risk loci at 2q35. A recent fine-scale mapping analysis to refine these associations resulted in 1 (signal 1), 5 (signal 2), ...
  • Systemic therapy for early breast cancer in older adults 

    Battisti, NML; Biganzoli, L (Ovid Technologies (Wolters Kluwer Health), 2021-06-28)
  • Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. 

    Rugo, HS; Lerebours, F; Ciruelos, E; Drullinsky, P; Ruiz-Borrego, M; Neven, P; Park, YH; Prat, A; Bachelot, T; Juric, D; Turner, N; Sophos, N; Zarate, JP; Arce, C; Shen, Y-M; Turner, S; Kanakamedala, H; Hsu, W-C; Chia, S
    <h4>Background</h4>Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are ...
  • Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper. 

    Battisti, NML; De Glas, N; Sedrak, MS; Loh, KP; Liposits, G; Soto-Perez-de-Celis, E; Krok-Schoen, JL; Menjak, IB; Ring, A
    The current standard of care for the management of estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer has been redefined by the introduction of cyclin-dependent kinase ...
  • Observational cohort study in older women with early breast cancer: use of radiation therapy and impact on health-related quality of life and mortality. 

    Matteo Luca Battisti, N; Hatton, MQ; Wr Reed, M; Herbert, E; Morgan, JL; Bradburn, M; Simcock, R; Walters, SJ; Collins, KA; Ward, SE; Holmes, GR; Burton, M; Lifford, KJ; Edwards, A; Robinson, TG; Martin, C; Chater, T; Pemberton, KJ; Brennan, A; Leung Cheung, K; Todd, A; Audisio, RA; Wright, J; Green, T; Revell, D; Gath, J; Horgan, K; Holcombe, C; Winter, MC; Naik, J; Parmeshwar, R; Gosney, MA; Thompson, AM; Wyld, L; Ring, A (2021-06-16)
    <h4>Background</h4>Radiotherapy reduces in-breast recurrence risk in early breast cancer (EBC) in older women. This benefit may be small and should be balanced against treatment effect and holistic patient assessment. This ...
  • COVID-19 vaccines in older adults with cancer: a Young International Society of Geriatric Oncology perspective. 

    Loh, KP; Soto-Perez-de-Celis, E; Mislang, AR; Chan, W-L; Battisti, NML
  • Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. 

    Dowsett, M; Ellis, MJ; Dixon, JM; Gluz, O; Robertson, J; Kates, R; Suman, VJ; Turnbull, AK; Nitz, U; Christgen, M; Kreipe, H; Kuemmel, S; Bliss, JM; Barry, P; Johnston, SR; Jacobs, SA; Ma, CX; Smith, IE; Harbeck, N (2020-06-08)
    Many patients with ER+ HER2- primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical ...
  • Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. 

    Carreira, S; Porta, N; Arce-Gallego, S; Seed, G; Llop-Guevara, A; Bianchini, D; Rescigno, P; Paschalis, A; Bertan, C; Baker, C; Goodall, J; Miranda, S; Riisnaes, R; Figueiredo, I; Ferreira, A; Pereira, R; Crespo, M; Gurel, B; Nava Rodrigues, D; Pettitt, SJ; Yuan, W; Serra, V; Rekowski, J; Lord, CJ; Hall, E; Mateo, J; de Bono, JS (2021-05-27)
    PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed ...
  • Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom. 

    Robbins, HA; Alcala, K; Swerdlow, AJ; Schoemaker, MJ; Wareham, N; Travis, RC; Crosbie, PAJ; Callister, M; Baldwin, DR; Landy, R; Johansson, M
    <h4>Background</h4>The National Health Service England (NHS) classifies individuals as eligible for lung cancer screening using two risk prediction models, PLCOm2012 and Liverpool Lung Project-v2 (LLPv2). However, no study ...

View more